Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 14/20 | 0.51 |
| ▸ | F3 | P13726 | 12/20 | 0.51 |
| ▸ | F10 | P00742 | 9/20 | 0.51 |
| ▸ | F11 | P03951 | 9/20 | 0.51 |
| ▸ | F2 | P00734 | 8/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.35 |
| ▸ | F9 | P00740 | 2/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2854982 | 0.94 | F7 (0.48) | F7F3F10F11F2 | |
| SCHEMBL2852770 | 0.93 | F7 (0.47) | F7F3F10F11F2 | |
| SCHEMBL2852631 | 0.90 | F7 (0.52) | F7F3F10F11F2 | |
| SCHEMBL2850919 | 0.90 | F7 (0.52) | F7F3F10F11F2 | |
| SCHEMBL2851039 | 0.89 | F7 (0.48) | F7F3F10F11F2 | |
| SCHEMBL2854595 | 0.89 | F7 (0.51) | F7F3F10F11F2 | |
| SCHEMBL5003720 | 0.88 | F7 (0.47) | F7F3F10F11F2 | |
| SCHEMBL2849051 | 0.87 | F7 (0.49) | F7F3F10F11F2 | |
| SCHEMBL5003040 | 0.86 | F7 (0.49) | F7F3F10F11F2 | |
| SCHEMBL2852655 | 0.86 | F7 (0.48) | F7F3F10F11F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910298-B1 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | F7 3/4885F3 10/4885F10 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.